<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25090">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02780128</url>
  </required_header>
  <id_info>
    <org_study_id>14-011071</org_study_id>
    <nct_id>NCT02780128</nct_id>
  </id_info>
  <brief_title>Next Generation Personalized Neuroblastoma Therapy</brief_title>
  <acronym>NEPENTHE</acronym>
  <official_title>Next Generation Personalized Neuroblastoma Therapy (The NEPENTHE Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yael P Mosse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Foundation Medicine</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to match genomic aberrations in tumor cells at time of
      relapse to rationally designed combinations of molecularly targeted agents. This study will
      be done in two parts:

      Part I: Tumor will be accessed at study entry via a biopsy and subjected to deep sequencing
      to identify protocol-specified biomarkers for therapy assignment.

      Part II: If the tumor contains a genetic change defined by the study as being actionable,
      and other criteria are met, participants will be assigned to therapy based upon the genetic
      changes identified in the tumor biopsy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">May 2026</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities when combining ceritinib combined with ribociclib</measure>
    <time_frame>28-day cycle one of therapy</time_frame>
    <description>The primary variable is the incidence of dose limiting toxicities (DLTs) during the first 28 days of therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events of trametinib as characterized and graded by CTCAE V4.03</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse events of single agent Trametinib in patients with RAS-driven relapsed/refractory neuroblastoma will be characterized and graded using the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities of HDM201</measure>
    <time_frame>28-day cycle one of therapy</time_frame>
    <description>The primary variable is the incidence of dose-limiting toxicities (DLTs) during the first 28 days of therapy. Estimation of the maximum tolerated dose (MTD) of HDM201 will be based upon the estimation of the probability of DLT during the first 21 days of therapy for patients in the dose-escalation portion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve from time zero to last quantifiable concentration</measure>
    <time_frame>Pre-dose, 1, 2, 4, 6, and 24 hours post first dose of cycle 1; pre-dose on day 8 of cycle 1</time_frame>
    <description>Area under the plasma concentration time-curve from zero to the last measured concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution at steady state</measure>
    <time_frame>pre-dose, 1, 2, 4, 6, and 24 hours on day 15 of cycle 1</time_frame>
    <description>The theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients with overall objective response</measure>
    <time_frame>2 years</time_frame>
    <description>To describe whether the assigned targeted therapy can mediate anti-tumor effects in subjects with relapsed or refractory high-risk neuroblastoma within the context of a phase 1/phase1b biomarker-driven trial. Percentage of patients with objective response will be according to the International Neuroblastoma Response Criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cataloguing of genomic alterations identified from biopsies performed at time of relapse in patients with relapsed or refractory neuroblastoma</measure>
    <time_frame>3 years</time_frame>
    <description>Neuroblastomas undergo substantial mutational evolution during therapy, and relapsed disease is more likely to be driven by a targetable oncogenic pathway. Genomic alterations measured by next-generation sequencing at time of disease progression will be characterized and reported in a descriptive manner.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">83</enrollment>
  <condition>Neuroblastoma</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Molecular Analysis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participants with relapsed or refractory neuroblastoma will have a tumor biopsy to identify genetic mutations. There is no drug given in this arm of the trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1- ALK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Qualified participants whose tumors show certain mutations in the anaplastic lymphoma kinase (ALK) pathway (based on genetic sequencing results) will receive a combination therapy of ceritinib and ribociclib, to be administered orally in 28-day cycles.
Participants will receive the same dose of ceritinib, but three different doses of ribociclib will be evaluated. Once the investigators have identified the highest safe dose of both drugs that can be given at the same time, additional participants will be enrolled in the study at this dose level.
It is possible that if participants start at a lower dose of ribociclib, participants may take a higher dose once that dose has been deemed safe.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2-RAS-MAPK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Qualified participants whose tumors show certain mutations in the rat sarcoma - mitogen activated protein kinase (RAS-MAPK) pathway (based on genetic sequencing results) will receive trametinib as a single agent, to be administered orally in 28-day cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3- p53</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Qualified participants that do not match Groups 1 or 2, and whose tumors show wild-type p53 (based on genetic sequencing results) will receive HDM201 as a single agent, to be administered orally on Day 1 and Day 8 in 28-day cycles.
The investigators will perform a dose-escalation of HDM201. Once the investigators have identified the highest safe dose of HDM201, additional participants will be enrolled in the study at this dose level.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsy</intervention_name>
    <description>Needle or incisional tumor biopsy</description>
    <arm_group_label>Molecular Analysis</arm_group_label>
    <other_name>Genetic Sequencing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceritinib</intervention_name>
    <description>Participants will take ceritinib once per day orally for 28 days.</description>
    <arm_group_label>Group 1- ALK</arm_group_label>
    <other_name>LDK378</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <description>Participants will take trametinib once per day orally for 28 days.</description>
    <arm_group_label>Group 2-RAS-MAPK</arm_group_label>
    <other_name>MEKINIST</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HDM201</intervention_name>
    <description>Participants will take HDM201 orally on Day 1 and Day 8 of a 28-day cycle.</description>
    <arm_group_label>Group 3- p53</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Next Generation Sequencing</intervention_name>
    <description>Tumor tissue will be sent to Foundation Medicine laboratory for molecular profiling.</description>
    <arm_group_label>Molecular Analysis</arm_group_label>
    <other_name>Molecular Profiling</other_name>
    <other_name>Genetic Sequencing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tumor Scans</intervention_name>
    <description>Participants will undergo different types of scans to look at your tumor. These scans include CT (computerized tomography), MIBG (meta-iodobenzylguanidine) PET (positron emission tomography), and MRI (magnetic resonance imaging). Participants may have more than one type of scan.</description>
    <arm_group_label>Molecular Analysis</arm_group_label>
    <arm_group_label>Group 1- ALK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>X-ray</intervention_name>
    <description>Participants will have x-rays of the wrist and leg.</description>
    <arm_group_label>Group 2-RAS-MAPK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone marrow Tests</intervention_name>
    <description>Participants will have needles inserted through their hip bone to remove fluid from inside the bone marrow. This test determines if participants have tumor in the bone marrow.</description>
    <arm_group_label>Group 1- ALK</arm_group_label>
    <arm_group_label>Group 2-RAS-MAPK</arm_group_label>
    <arm_group_label>Group 3- p53</arm_group_label>
    <other_name>Bone marrow aspiration</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physical Exam</intervention_name>
    <description>The exam includes taking participant weight, height, blood pressure, heart rate and respiratory rate and performing a examination of the participants body. The investigators may also check the participants vision with an eye chart.</description>
    <arm_group_label>Molecular Analysis</arm_group_label>
    <arm_group_label>Group 1- ALK</arm_group_label>
    <arm_group_label>Group 2-RAS-MAPK</arm_group_label>
    <arm_group_label>Group 3- p53</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Eye Exam</intervention_name>
    <description>Participants will have their eyes will be evaluated using different instruments. Participants will also be asked to read an eye chart. The exams will take about 15 minutes.</description>
    <arm_group_label>Group 2-RAS-MAPK</arm_group_label>
    <other_name>Ophthalmic Exam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Labs</intervention_name>
    <description>Standard blood tests will be done to measure different types of blood cells, to measure the amount of certain substances, and tests to check how well liver and kidneys are working. When possible, the investigators will take blood from the participants central line. If this is not possible, the investigators will take blood from a vein in the participants arm. First, the investigators will put some cream on the skin so that drawing blood will not be painful. Then the investigators will put a thin needle into the vein to draw the blood.</description>
    <arm_group_label>Molecular Analysis</arm_group_label>
    <arm_group_label>Group 1- ALK</arm_group_label>
    <arm_group_label>Group 2-RAS-MAPK</arm_group_label>
    <arm_group_label>Group 3- p53</arm_group_label>
    <other_name>Blood tests</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pregnancy Test</intervention_name>
    <description>If the participant is 11 years old or older or has already started having periods, the participant will be asked to take a pregnancy test before starting this study. The results will be shared with the participant but not with the participants' parent(s). We strongly encourage the participant to share the results with the parents. If the participant is found to be pregnant, the participant will not be able to continue participation in the study. About 1 teaspoon of blood (or urine if a urine test) will be needed.</description>
    <arm_group_label>Molecular Analysis</arm_group_label>
    <arm_group_label>Group 1- ALK</arm_group_label>
    <arm_group_label>Group 2-RAS-MAPK</arm_group_label>
    <arm_group_label>Group 3- p53</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Interviews</intervention_name>
    <description>A team member will take the participant's medical history, along with a listing of any medications that are being taken. Throughout the study, participants will be asked to report if they think that anything bad has happened as a result of the study.</description>
    <arm_group_label>Molecular Analysis</arm_group_label>
    <arm_group_label>Group 1- ALK</arm_group_label>
    <arm_group_label>Group 2-RAS-MAPK</arm_group_label>
    <arm_group_label>Group 3- p53</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ECG</intervention_name>
    <description>This is a test of electrical activity of the heart. The investigators will put electrodes (sticky pads attached to wires) on the participant's chest, arms and legs. The electrocardiogram (ECG) will not be uncomfortable, but the participant will have to lie still. It does not hurt and takes about 15 minutes.</description>
    <arm_group_label>Group 1- ALK</arm_group_label>
    <arm_group_label>Group 2-RAS-MAPK</arm_group_label>
    <arm_group_label>Group 3- p53</arm_group_label>
    <other_name>EKG</other_name>
    <other_name>electrocardiogram</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>echocardiogram</intervention_name>
    <description>The participant will have an ultrasound of the heart taken to assess heart function. The investigators will put some gel on the skin and use a machine to take pictures of the heart.</description>
    <arm_group_label>Group 1- ALK</arm_group_label>
    <arm_group_label>Group 2-RAS-MAPK</arm_group_label>
    <arm_group_label>Group 3- p53</arm_group_label>
    <other_name>echo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribociclib</intervention_name>
    <description>Participants will take ribociclib once per day orally for 21 days, followed by 7 days rest.</description>
    <arm_group_label>Group 1- ALK</arm_group_label>
    <other_name>LEE011</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &lt;1 year old

          -  Relapsed or refractory neuroblastoma

          -  A sufficient interval between the last dose of prior anti-cancer therapy (including
             cytotoxic and biological therapies) and enrollment in this study, to allow recovery
             from the acute toxic effects of all prior anti-cancer therapy. Please contact site
             for specific details

          -  Adequate bone marrow function (bone marrow may be involved with tumor. Contact site
             for specific details)

          -  Adequate renal function, defined as Creatinine clearance or radioisotope glomerular
             filtration rate (GFR) ≥ 70 mL/min/1.73 m2 OR serum creatinine based on age/gender
             normal (contact site for details)

          -  Adequate liver function, defined as total serum bilirubin 1.5 times the upper limit
             of normal AND alanine transaminase (ALT) ≤ 110 U/L.

          -  Adequate cardiac function, defined as corrected QT interval (QTc) ≤ 480 msec AND
             shortening fraction &gt; 27%

          -  Males and females who are sexually active must agree to use effective contraception
             during and for 3 months after treatment

        Exclusion Criteria:

          -  Subjects taking certain drugs or herbal medications that impact drug metabolism
             and/or cardiac function that cannot be discontinued (contact site for details).

          -  Subjects with concurrent severe and/or uncontrolled concurrent medical conditions
             that could compromise participation in the study (contact site for details)

          -  Corticosteroids initiated for tumor therapy within 7 days prior to study enrollment

          -  Other anti-cancer agents

          -  Other investigational drugs

          -  Radiation therapy

          -  Subjects &lt; 0.5m2

          -  Pregnant or lactating females

          -  Sexually active males unless they use a condom during intercourse while taking study
             drug/s and for 3 months after study drug discontinuation and thus do not attempt to
             father a child in this period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yael P Mosse', MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia, The University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John M Maris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia, The University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominique R Cross, MPH</last_name>
    <phone>2674252131</phone>
    <email>crossd2@email.chop.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique R Cross, MPH</last_name>
      <phone>267-425-2131</phone>
      <email>crossd2@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Yael P Mosse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John M Maris, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rochelle Bagatell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Schramm A, Köster J, Assenov Y, Althoff K, Peifer M, Mahlow E, Odersky A, Beisser D, Ernst C, Henssen AG, Stephan H, Schröder C, Heukamp L, Engesser A, Kahlert Y, Theissen J, Hero B, Roels F, Altmüller J, Nürnberg P, Astrahantseff K, Gloeckner C, De Preter K, Plass C, Lee S, Lode HN, Henrich KO, Gartlgruber M, Speleman F, Schmezer P, Westermann F, Rahmann S, Fischer M, Eggert A, Schulte JH. Mutational dynamics between primary and relapse neuroblastomas. Nat Genet. 2015 Aug;47(8):872-7. doi: 10.1038/ng.3349. Epub 2015 Jun 29.</citation>
    <PMID>26121086</PMID>
  </reference>
  <reference>
    <citation>Rader J, Russell MR, Hart LS, Nakazawa MS, Belcastro LT, Martinez D, Li Y, Carpenter EL, Attiyeh EF, Diskin SJ, Kim S, Parasuraman S, Caponigro G, Schnepp RW, Wood AC, Pawel B, Cole KA, Maris JM. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82. doi: 10.1158/1078-0432.CCR-13-1675. Epub 2013 Sep 17.</citation>
    <PMID>24045179</PMID>
  </reference>
  <reference>
    <citation>Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, Michellys PY, Awad MM, Yanagitani N, Kim S, Pferdekamper AC, Li J, Kasibhatla S, Sun F, Sun X, Hua S, McNamara P, Mahmood S, Lockerman EL, Fujita N, Nishio M, Harris JL, Shaw AT, Engelman JA. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014 Jun;4(6):662-73. doi: 10.1158/2159-8290.CD-13-0846. Epub 2014 Mar 27.</citation>
    <PMID>24675041</PMID>
  </reference>
  <reference>
    <citation>Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VG, Le NT, Hart L, Bendell JC, Eckhardt G, Kurzrock R, Flaherty K, Burris HA 3rd, Messersmith WA. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012 Aug;13(8):773-81. doi: 10.1016/S1470-2045(12)70270-X. Epub 2012 Jul 16.</citation>
    <PMID>22805291</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 4, 2017</lastchanged_date>
  <firstreceived_date>May 11, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Philadelphia</investigator_affiliation>
    <investigator_full_name>Yael P Mosse</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>neuroblastoma</keyword>
  <keyword>cancer</keyword>
  <keyword>genetic profiling</keyword>
  <keyword>ceritinib</keyword>
  <keyword>ribociclib</keyword>
  <keyword>trametinib</keyword>
  <keyword>HDM201</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Ceritinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
